Biotech · Private company
Achillion, a wholly owned subsidiary of Alexion
Track this companyFree. Adds Achillion, a wholly owned subsidiary of Alexion to your Dealase workspace and tells you when its record changes.
Clinical trials140 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials14
- A Drug Interaction Study of ACH-0145228PHASE1 · COMPLETED · started Dec 22, 2019ClinicalTrials.gov NCT04709081 · fetched Nov 12, 2026
- A Drug Interaction Study of DanicopanPHASE1 · COMPLETED · started Jul 28, 2019ClinicalTrials.gov NCT04709094 · fetched Nov 12, 2026
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy AdultsPHASE1 · COMPLETED · started Jul 27, 2018ClinicalTrials.gov NCT05109390 · fetched Nov 12, 2026
- A Study of the Cardiac Effects of Danicopan in Healthy AdultsPHASE1 · COMPLETED · started Jul 26, 2018ClinicalTrials.gov NCT05016206 · fetched Nov 12, 2026
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabPHASE2 · COMPLETED · started May 8, 2018ClinicalTrials.gov NCT03472885 · fetched Nov 12, 2026
- Study of Danicopan in Participants With Hepatic ImpairmentPHASE1 · COMPLETED · started May 1, 2018ClinicalTrials.gov NCT03555539 · fetched Nov 12, 2026
- Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney DysfunctionPHASE1 · COMPLETED · started Jan 24, 2018ClinicalTrials.gov NCT04935294 · fetched Nov 12, 2026
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive ParticipantsPHASE2 · COMPLETED · started Sep 1, 2010ClinicalTrials.gov NCT01180790 · fetched Nov 12, 2026
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine TreatmentPHASE2 · COMPLETED · started May 1, 2008ClinicalTrials.gov NCT00675844 · fetched Nov 12, 2026
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C InfectionPHASE2 · TERMINATED · started Nov 30, 2006ClinicalTrials.gov NCT00401947 · fetched Nov 12, 2026
- Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014APHASE2 · COMPLETED · started Sep 1, 2006ClinicalTrials.gov NCT00380159 · fetched Nov 12, 2026
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive ParticipantsPHASE2 · COMPLETED · started May 1, 2006ClinicalTrials.gov NCT00350272 · fetched Nov 12, 2026
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V MutationPHASE1_PHASE2 · COMPLETED · started Mar 31, 2006ClinicalTrials.gov NCT00312039 · fetched Nov 12, 2026
- Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis BPHASE2 · TERMINATED · started Jul 1, 2002ClinicalTrials.gov NCT00040144 · fetched Nov 12, 2026